Biohaven (BHVN)

• Market cap: $2.19B
• 1 day: 1.10%
• 5 days: -0.81%
• 1 month: -7.99%
• 3 months: -43.28%
• 6 months: -56.16%
• Year to date: -40.67%
• 1 year: -42.99%
• 5 years: -85.42%
• 10 years: -85.42%
• Sector: Healthcare
• Industry: Biotechnology

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

98% more call options, than puts

Call options by funds: $34.9M | Put options by funds: $17.6M

61% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 64

15% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 40

0.91% more ownership

Funds ownership: 91.1% [Q3] → 92.01% (+0.91%) [Q4]

0% more funds holding

Funds holding: 253 [Q3] → 254 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 10 (+0) [Q4]

18% less capital invested

Capital invested by funds: $4.3B [Q3] → $3.51B (-$792M) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $54 144% upside
• Avg. target: $61 177% upside
• High target: $68 207% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

Baird Brian Skorney 35% 1-year accuracy 8 / 23 met price target	158% upside $57	Outperform Maintained	28 Apr 2025
Morgan Stanley Terence Flynn 50% 1-year accuracy 11 / 22 met price target	185% upside $63	Overweight Maintained	7 Mar 2025
JP Morgan Tessa Romero 23% 1-year accuracy 3 / 13 met price target	207% upside $68	Overweight Maintained	5 Mar 2025
HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 44 / 171 met price target	144% upside $54	Buy Reiterated	4 Mar 2025
RBC Capital Leonid Timashev 21% 1-year accuracy 9 / 42 met price target	176% upside $61	Outperform Reiterated	4 Mar 2025